Valuation: SCYNEXIS, Inc.

Market Cap 36.05M 31.44M 29.32M 26.97M 50.61M 3.45B 51.81M 348M 136M 1.71B 135M 132M 5.89B P/E 2026 *
-0.89x
P/E 2027 * -1.44x
Enterprise Value 36.05M 31.44M 29.32M 26.97M 50.61M 3.45B 51.81M 348M 136M 1.71B 135M 132M 5.89B EV / Sales 2026 *
31.2x
EV / Sales 2027 * 5.4x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+3.86%
1 week-6.91%
Current month-7.37%
1 month-2.08%
3 months-52.20%
6 months-39.16%
Current year-25.48%
1 week 3.53
Extreme 3.53
4.11
1 month 3.53
Extreme 3.53
5.1
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
10.48
3 years 3.53
Extreme 3.53
30.96
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
440.8
Manager TitleAgeSince
Chief Executive Officer 61 31/12/2022
Director of Finance/CFO 65 23/10/2022
Chief Tech/Sci/R&D Officer - 30/09/2020
Director TitleAgeSince
Director/Board Member 73 30/11/2008
Chairman 67 03/06/2015
Director/Board Member 61 31/12/2022
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Free

Director

5,750 0.0579%
26/06/26 Free

Director

5,750 0.0579%
26/06/26 Free

Director

5,750 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
+3.86%-6.91%-35.67%-83.92% 36.05M
-0.87%+2.94%+49.73%+163.92% 1,089B
-0.45%+5.95%+59.75%+52.18% 643B
+0.04%+2.81%+39.67%+74.54% 465B
-1.69%+8.36%+38.80%+34.26% 359B
-0.51%+3.35%+39.00%+43.76% 303B
+1.50%+5.14%+21.72%+18.77% 267B
+0.79%+4.32%-25.07%-36.02% 226B
-1.39%+5.84%+28.66%+64.00% 212B
-1.18%+1.88%+17.43%+72.69% 167B
Average -0.18%+4.57%+23.40%+40.42% 373.12B
Weighted average by Cap. -0.68%+5.14%+39.10%+79.01%

Financials

2026 *2027 *
Net sales 1.15M 1.01M 939K 863K 1.62M 110M 1.66M 11.13M 4.35M 54.7M 4.33M 4.24M 189M 6.68M 5.82M 5.43M 5M 9.37M 639M 9.6M 64.4M 25.17M 316M 25.07M 24.53M 1.09B
Net income -41.07M -35.82M -33.41M -30.73M -57.66M -3.93B -59.03M -396M -155M -1.95B -154M -151M -6.71B -28.73M -25.06M -23.37M -21.49M -40.33M -2.75B -41.29M -277M -108M -1.36B -108M -106M -4.69B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
29/07/26 US$3.770 +3.86% 46,971
28/07/26 US$3.630 +1.68% 27,183
27/07/26 US$3.570 -4.29% 103,762
24/07/26 US$3.730 -5.81% 91,074
23/07/26 US$3.960 +0.13% 31,947
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.770USD
Average target price
33.55USD
Spread / Average Target
+789.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock